NCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
8 trialsNCT02533674 2021-06-11
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01341457 2019-03-01
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT03503604 2018-04-20
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Phase 1 Unknown
NCT00887757 2017-11-21
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00550199 2013-08-19
LBH589 and Gemcitabine in the Treatment of Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT00500422 2013-02-13
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00413686 2010-12-06
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed